# TQB2102-II-04 (NCT06767800)

> A Clinical Trial Evaluating TQB2102 for Injection in Combination With Behmosubaisumab/Payamprolizumab With or Without Chemotherapy in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal Adenocarcinoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06767800
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- Conditions: Gastroesophageal Adenocarcinoma
- Interventions: TQB2102 for injection (7.5 mg) +Benmelstobart+Chemotherapy; TQB2102 for injection (6 mg/7.5 mg) +Benmelstobart+Chemotherapy; TQB2102 for injection (6 mg/7.5 mg) +Penpulimab+Chemotherapy
- Enrollment: 204
- Primary outcome: Objective Response Rate (ORR)

## Indexed commentary on TQB2102-II-04 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=tqb2102-ii-04-nct06767800